New hope for hard-to-treat leukemia: experimental drug enters final testing phase
Disease control
Not yet recruiting
This study tests a new drug called TGRX-678 in people with chronic myeloid leukemia (CML) whose cancer has stopped responding to or caused side effects from at least three prior treatments. About 180 adults will receive either TGRX-678 or another standard drug chosen by their doc…
Phase: PHASE3 • Sponsor: Shenzhen TargetRx Co., Ltd. • Aim: Disease control
Last updated May 06, 2026 16:03 UTC